Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

21st Century Cures Revisions Tell FDA To Highlight ‘Patient Experience Data’

Executive Summary

Lame-duck passage is goal of changes to reform legislation, which now includes highly targeted funding for FDA.

You may also be interested in...



PDUFA Acronym War Begins: Could Reauthorization Be Called Patient-UFA?

For first time ever, the administration that negotiated a user fee agreement won’t be shepherding its reauthorization through Congress.

Patient Advocacy With FDA Review Staff Will Be Tougher Post-Sarepta

Efforts by CDER management to encourage more interaction between patients and FDA reviewers may be part of the collateral damage from the difficult FDA review of Sarepta’s Exondys 51. The hopes of parents of boys with DMD pushed the regulatory flexibility by CDER management on this application – but may end up limiting the willingness of FDA reviewers to engage with patients in the future.

REMS Abuse Legislation: GPhA and PhRMA Set To Battle Again

Senate bill would allow generic companies to bring civil suits against brand sponsors that use REMS requirements to avoid providing samples for testing.

Topics

Related Companies

UsernamePublicRestriction

Register

GB002453

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel